Intracranial treatment of neuropsychiatric disorders by clostridial neurotoxins such as botulinum toxin

Details for Australian Patent Application No. 2003221922 (hide)

International Classifications

Event Publications

7 August 2003 Complete Application Filed

Priority application(s): 10/143,078 10.05.02 US

15 January 2004 Application Open to Public Inspection

Published as AU-B-2003221922

28 September 2006 Application Accepted

Published as AU-B-2003221922

18 January 2007 Opposition Lodged

Solstice Neurosciences, Inc. has lodged an opposition against Allergan, Inc.

31 May 2007 Opposition Withdrawn

The opposition by Solstice Neurosciences, Inc. against Allergan, Inc has been withdrawn.

5 July 2007 Standard Patent Sealed

18 June 2009 Corrigenda

Applications Accepted - Name Index Under the name Allergan, Inc., Application No. 2003221922, under INID (43) correct Publication Date to read 24 November 2003.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.